Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Gains from Sales and Divestitures (2016 - 2024)

Historic Gains from Sales and Divestitures for Lemaitre Vascular (LMAT) over the last 13 years, with Q4 2024 value amounting to $14266.0.

  • Lemaitre Vascular's Gains from Sales and Divestitures fell 7112.15% to $14266.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $14266.0, marking a year-over-year decrease of 7112.15%. This contributed to the annual value of $14266.0 for FY2024, which is 7112.15% down from last year.
  • As of Q4 2024, Lemaitre Vascular's Gains from Sales and Divestitures stood at $14266.0, which was down 7112.15% from $49400.0 recorded in Q4 2023.
  • In the past 5 years, Lemaitre Vascular's Gains from Sales and Divestitures ranged from a high of $51414.0 in Q4 2021 and a low of $14266.0 during Q4 2024
  • For the 5-year period, Lemaitre Vascular's Gains from Sales and Divestitures averaged around $42247.6, with its median value being $49400.0 (2023).
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first surged by 859.77% in 2023, then plummeted by 7112.15% in 2024.
  • Over the past 5 years, Lemaitre Vascular's Gains from Sales and Divestitures (Quarter) stood at $50669.0 in 2020, then grew by 1.47% to $51414.0 in 2021, then decreased by 11.52% to $45489.0 in 2022, then grew by 8.6% to $49400.0 in 2023, then crashed by 71.12% to $14266.0 in 2024.
  • Its Gains from Sales and Divestitures stands at $14266.0 for Q4 2024, versus $49400.0 for Q4 2023 and $45489.0 for Q4 2022.